ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aligos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.84−0.02 (-0.41%)
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
Price history
Daily open, high, low, close and volume
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Daily prices are not in StockData yet. This table fills in once an end-of-day price source is connected. | ||||||
Stock splits
From SEC filings
| Date | Ratio | Effect on per-share figures |
|---|---|---|
| Aug 19, 2024 | 1-for-25 reverse | Earlier per-share figures multiplied by 25 |
| Aug 19, 2024 | 1-for-25 reverse | Earlier per-share figures multiplied by 25 |